Cargando…

The severity and risk factors for mortality in immunocompromised adult patients hospitalized with influenza-related pneumonia

OBJECTIVE: To explore disease severity and risk factors for 30-day mortality of adult immunocompromised (IC) patients hospitalized with influenza-related pneumonia (Flu-p). METHOD: A total of 122 IC and 1191 immunocompetent patients hospitalized with Flu-p from January 2012 to December 2018 were rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Liang, Han, Xiudi, Li, YanLi, Zhang, Chunxiao, Xing, Xiqian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8383249/
https://www.ncbi.nlm.nih.gov/pubmed/34429126
http://dx.doi.org/10.1186/s12941-021-00462-7
_version_ 1783741699580755968
author Chen, Liang
Han, Xiudi
Li, YanLi
Zhang, Chunxiao
Xing, Xiqian
author_facet Chen, Liang
Han, Xiudi
Li, YanLi
Zhang, Chunxiao
Xing, Xiqian
author_sort Chen, Liang
collection PubMed
description OBJECTIVE: To explore disease severity and risk factors for 30-day mortality of adult immunocompromised (IC) patients hospitalized with influenza-related pneumonia (Flu-p). METHOD: A total of 122 IC and 1191 immunocompetent patients hospitalized with Flu-p from January 2012 to December 2018 were recruited retrospectively from five teaching hospitals in China. RESULTS: After controlling for confounders, multivariate logistic regression analysis showed that immunosuppression was associated with increased risks for invasive ventilation [odds ratio: (OR) 2.475, 95% confidence interval (CI): 1.511–4.053, p < 0.001], admittance to the intensive care unit (OR: 3.247, 95% CI 2.064–5.106, p < 0.001), and 30-day mortality (OR: 3.206, 95% CI 1.926–5.335, p < 0.001) in patients with Flu-p. Another multivariate logistic regression model revealed that baseline lymphocyte counts (OR: 0.993, 95% CI 0.990–0.996, p < 0.001), coinfection (OR: 5.450, 95% CI 1.638–18.167, p = 0.006), early neuraminidase inhibitor therapy (OR 0.401, 95% CI 0.127–0.878, p = 0.001), and systemic corticosteroid use at admission (OR: 6.414, 95% CI 1.348–30.512, p = 0.020) were independently related to 30-day mortality in IC patients with Flu-p. Based on analysis of the receiver operating characteristic curve (ROC), the optimal cutoff for lymphocyte counts was 0.6 × 10(9)/L [area under the ROC (AUROC) = 0.824, 95% CI 0.744—0.887], sensitivity: 97.8%, specificity: 73.7%]. CONCLUSIONS: IC conditions are associated with more severe outcomes in patients with Flu-p. The predictors for mortality that we identified may be valuable for the management of Flu-p among IC patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12941-021-00462-7.
format Online
Article
Text
id pubmed-8383249
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-83832492021-08-24 The severity and risk factors for mortality in immunocompromised adult patients hospitalized with influenza-related pneumonia Chen, Liang Han, Xiudi Li, YanLi Zhang, Chunxiao Xing, Xiqian Ann Clin Microbiol Antimicrob Research OBJECTIVE: To explore disease severity and risk factors for 30-day mortality of adult immunocompromised (IC) patients hospitalized with influenza-related pneumonia (Flu-p). METHOD: A total of 122 IC and 1191 immunocompetent patients hospitalized with Flu-p from January 2012 to December 2018 were recruited retrospectively from five teaching hospitals in China. RESULTS: After controlling for confounders, multivariate logistic regression analysis showed that immunosuppression was associated with increased risks for invasive ventilation [odds ratio: (OR) 2.475, 95% confidence interval (CI): 1.511–4.053, p < 0.001], admittance to the intensive care unit (OR: 3.247, 95% CI 2.064–5.106, p < 0.001), and 30-day mortality (OR: 3.206, 95% CI 1.926–5.335, p < 0.001) in patients with Flu-p. Another multivariate logistic regression model revealed that baseline lymphocyte counts (OR: 0.993, 95% CI 0.990–0.996, p < 0.001), coinfection (OR: 5.450, 95% CI 1.638–18.167, p = 0.006), early neuraminidase inhibitor therapy (OR 0.401, 95% CI 0.127–0.878, p = 0.001), and systemic corticosteroid use at admission (OR: 6.414, 95% CI 1.348–30.512, p = 0.020) were independently related to 30-day mortality in IC patients with Flu-p. Based on analysis of the receiver operating characteristic curve (ROC), the optimal cutoff for lymphocyte counts was 0.6 × 10(9)/L [area under the ROC (AUROC) = 0.824, 95% CI 0.744—0.887], sensitivity: 97.8%, specificity: 73.7%]. CONCLUSIONS: IC conditions are associated with more severe outcomes in patients with Flu-p. The predictors for mortality that we identified may be valuable for the management of Flu-p among IC patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12941-021-00462-7. BioMed Central 2021-08-24 /pmc/articles/PMC8383249/ /pubmed/34429126 http://dx.doi.org/10.1186/s12941-021-00462-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Chen, Liang
Han, Xiudi
Li, YanLi
Zhang, Chunxiao
Xing, Xiqian
The severity and risk factors for mortality in immunocompromised adult patients hospitalized with influenza-related pneumonia
title The severity and risk factors for mortality in immunocompromised adult patients hospitalized with influenza-related pneumonia
title_full The severity and risk factors for mortality in immunocompromised adult patients hospitalized with influenza-related pneumonia
title_fullStr The severity and risk factors for mortality in immunocompromised adult patients hospitalized with influenza-related pneumonia
title_full_unstemmed The severity and risk factors for mortality in immunocompromised adult patients hospitalized with influenza-related pneumonia
title_short The severity and risk factors for mortality in immunocompromised adult patients hospitalized with influenza-related pneumonia
title_sort severity and risk factors for mortality in immunocompromised adult patients hospitalized with influenza-related pneumonia
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8383249/
https://www.ncbi.nlm.nih.gov/pubmed/34429126
http://dx.doi.org/10.1186/s12941-021-00462-7
work_keys_str_mv AT chenliang theseverityandriskfactorsformortalityinimmunocompromisedadultpatientshospitalizedwithinfluenzarelatedpneumonia
AT hanxiudi theseverityandriskfactorsformortalityinimmunocompromisedadultpatientshospitalizedwithinfluenzarelatedpneumonia
AT liyanli theseverityandriskfactorsformortalityinimmunocompromisedadultpatientshospitalizedwithinfluenzarelatedpneumonia
AT zhangchunxiao theseverityandriskfactorsformortalityinimmunocompromisedadultpatientshospitalizedwithinfluenzarelatedpneumonia
AT xingxiqian theseverityandriskfactorsformortalityinimmunocompromisedadultpatientshospitalizedwithinfluenzarelatedpneumonia
AT chenliang severityandriskfactorsformortalityinimmunocompromisedadultpatientshospitalizedwithinfluenzarelatedpneumonia
AT hanxiudi severityandriskfactorsformortalityinimmunocompromisedadultpatientshospitalizedwithinfluenzarelatedpneumonia
AT liyanli severityandriskfactorsformortalityinimmunocompromisedadultpatientshospitalizedwithinfluenzarelatedpneumonia
AT zhangchunxiao severityandriskfactorsformortalityinimmunocompromisedadultpatientshospitalizedwithinfluenzarelatedpneumonia
AT xingxiqian severityandriskfactorsformortalityinimmunocompromisedadultpatientshospitalizedwithinfluenzarelatedpneumonia